Fiessinger JN - Search Results

1

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS; THRIVE Treatment Study Investigators. Fiessinger JN, et al. JAMA. 2005 Feb 9;293(6):681-9. doi: 10.1001/jama.293.6.681. JAMA. 2005. PMID: 15701909 Clinical Trial.

2

Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study.

Fiessinger JN, Bounameaux H, Cairols MA, Clement DL, Coccheri S, Fletcher JP, Hoffmann U, Turpie AG; TAIPAD investigators. Fiessinger JN, et al. J Thromb Haemost. 2010 Nov;8(11):2369-76. doi: 10.1111/j.1538-7836.2010.04020.x. J Thromb Haemost. 2010. PMID: 20723034 Free article. Clinical Trial.

3

Double-blind, randomized comparison of systemic continuous infusion of 0.25 versus 0.50 mg/kg/24 h of alteplase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) trial.

Bounameaux H, Banga JD, Bluhmki E, Coccheri S, Fiessinger JN, Haarmann W, Lockner D, Mahler F, Ninet J, Schneider PA, et al. Bounameaux H, et al. Among authors: fiessinger jn. Thromb Haemost. 1992 Mar 2;67(3):306-9. Thromb Haemost. 1992. PMID: 1641820 Clinical Trial.

4

Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.

Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D; SACRE Study Investigators. Samama CM, et al. Among authors: fiessinger jn. Arch Intern Med. 2002 Oct 28;162(19):2191-6. doi: 10.1001/archinte.162.19.2191. Arch Intern Med. 2002. PMID: 12390061 Clinical Trial.

5

[New antithrombotic agents. Towards a new therapeutic plan].

Fiessinger JN. Fiessinger JN. Rev Prat. 2003 May 15;53(10):1063-4. Rev Prat. 2003. PMID: 12846024 French. No abstract available.

6

[New oral anticoagulants: prospects].

Fiessinger JN. Fiessinger JN. Rev Prat. 2010 May 20;60(5):613-6. Rev Prat. 2010. PMID: 20564841 French.

7

Cleaved protein S (PS), total PS, free PS, and activated protein C cofactor activity as risk factors for venous thromboembolism.

Borgel D, Reny JL, Fischelis D, Gandrille S, Emmerich J, Fiessinger JN, Aiach M. Borgel D, et al. Among authors: fiessinger jn. Clin Chem. 2003 Apr;49(4):575-80. doi: 10.1373/49.4.575. Clin Chem. 2003. PMID: 12651809

8

Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P. Ong KT, et al. Among authors: fiessinger jn. Lancet. 2010 Oct 30;376(9751):1476-84. doi: 10.1016/S0140-6736(10)60960-9. Epub 2010 Sep 7. Lancet. 2010. PMID: 20825986 Clinical Trial.

9

[Medical treatment of critical leg ischemia: current status and future perspectives of gene and cell therapy].

Emmerich J, Fiessinger JN. Emmerich J, et al. Among authors: fiessinger jn. Bull Acad Natl Med. 2006 Mar;190(3):667-80; discussion 680-1, 683-4. Bull Acad Natl Med. 2006. PMID: 17140102 Review. French.

10

[Treatment perspectives for critical limb ischemia: gene and cell therapy].

Pasqualoni E, Messas E, Fiessinger JN, Emmerich J. Pasqualoni E, et al. Among authors: fiessinger jn. Presse Med. 2008 Jun;37(6 Pt 2):1039-46. doi: 10.1016/j.lpm.2008.02.009. Epub 2008 May 2. Presse Med. 2008. PMID: 18450413 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

350 results

Search Page